Keyphrases
DNA Damage
100%
Ovarian Cancer
100%
Carboplatin
100%
PARP Inhibitor (PARPi)
100%
Replication Stress
100%
Sensitivity to Chemotherapy
100%
AXL Inhibition
100%
Ovarian Cancer Cells
75%
High-grade Serous Ovarian Cancer (HGSOC)
50%
Tumor Burden
50%
Cancer Cell Survival
50%
Homologous Recombination Proficient
50%
Tumor Samples
25%
Chemotherapy Response
25%
Receptor Tyrosine Kinase
25%
Chemotherapy
25%
Homologous Recombination Deficiency
25%
Serum Samples
25%
FDA-approved Drugs
25%
Response Predictors
25%
Sequestration
25%
Tumor Response
25%
Paclitaxel
25%
Homologous Recombination
25%
Chemotherapy Alone
25%
Patient Survival
25%
Platinum Resistance
25%
Platinum-based Chemotherapy
25%
Over 80
25%
Tumor Resistance
25%
Patient Tumor
25%
Response to Chemotherapy
25%
Replication Fork Progression
25%
Patient Serum
25%
Resistance to Chemotherapy
25%
DNA Replication Fork
25%
Olaparib
25%
Taxane-based Chemotherapy
25%
RAD51 Foci
25%
Chemoresponse
25%
Medicine and Dentistry
DNA Damage
100%
Ovarian Cancer
100%
Poly ADP Ribose Polymerase
100%
Neoplasm
57%
Carboplatin
57%
Homologous Recombination
57%
Cancer Cell
42%
PARP Inhibitor
42%
In Vitro
28%
Cell Survival
28%
Protein Tyrosine Kinase
14%
Paclitaxel
14%
Tumor Resistance
14%
DNA Synthesis
14%
Olaparib
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Ovary Cancer
100%
Neoplasm
57%
Carboplatin
57%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
42%
Protein Tyrosine Kinase
14%
Paclitaxel
14%
Tumor Resistance
14%
Olaparib
14%
Taxane
14%
Diseases
14%